Curocell (XKRX:372320) Debt-to-Asset : 0.52 (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Curocell Debt-to-Asset?

Curocell's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩35,684.11 Mil. Curocell's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩1,615.81 Mil. Curocell's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩72,021.28 Mil. Curocell's debt to asset for the quarter that ended in Dec. 2024 was 0.52.

Curocell Debt-to-Asset Historical Data

The historical data trend for Curocell's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Debt-to-Asset Chart

Curocell Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.06

0.12

0.33

0.41

0.52

Curocell Quarterly Data
	Dec19	Dec20	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial							0.41	0.45	0.43	0.48	0.52

Competitive Comparison of Curocell's Debt-to-Asset

For the Biotechnology subindustry, Curocell's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curocell's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curocell's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Curocell's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Curocell Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Curocell's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(35684.112	+	1615.812)	/	72021.277
	=	0.52

Curocell's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(35684.112	+	1615.812)	/	72021.277
	=	0.52

Curocell (XKRX:372320) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Curocell Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Curocell's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Curocell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002

Website

https://www.curocellbtx.com

Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell Headlines

No Headlines